Ajanta Pharma Limited
AJANTPHARM · Pharma · NSE
₹3,075
Current Market Price
Fair Value (DCF)
₹1,276
Discount to FV
-58.5%
Updated just now
YieldIQ Score
32/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
53%
ROE
23.3%
Debt/Equity
0.06
WACC
9.5%
Market Cap
₹38,416 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
32.7%
Return on capital employed
EV / EBITDA
22.5×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
58.4×
EBIT covers interest
Current Ratio
2.85×
Short-term liquidity
Asset Turnover
1.02×
Revenue per ₹ of assets
Revenue CAGR (3Y)
5.8%
3-year revenue growth
Revenue CAGR (5Y)
8.5%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹3,074.9
Bear case
Discount -312.7%
Base case
Discount -140.9%
Bull case
Discount -86.7%
Ratio Trends
AJANTPHARM · last 9 annual periods
ROE
23.3%
ROCE
32.7%
Operating Margin
—
Debt / Equity
0.06×
PE
33.2×
EV / EBITDA
22.5×
Historical Financials
AJANTPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3284 Cr | ₹3708 Cr | ₹4162 Cr | ₹4648 Cr | ₹5453 Cr | +13.5% |
| EBITDA | ₹1045 Cr | ₹882 Cr | ₹1257 Cr | ₹1354 Cr | ₹1567 Cr | +10.7% |
| EBIT | ₹920 Cr | ₹751 Cr | ₹1121 Cr | — | — | +5.1% |
| PAT | ₹713 Cr | ₹588 Cr | ₹816 Cr | ₹920 Cr | ₹1056 Cr | +10.3% |
| EPS (diluted) | ₹82.45 | ₹45.89 | ₹64.77 | — | — | -5.9% |
| CFO | ₹562 Cr | ₹792 Cr | ₹785 Cr | ₹1157 Cr | ₹529 Cr | -1.5% |
| CapEx | ₹-149 Cr | ₹-174 Cr | ₹-152 Cr | ₹-318 Cr | ₹-365 Cr | — |
| FCF | ₹413 Cr | ₹618 Cr | ₹633 Cr | ₹839 Cr | ₹164 Cr | -20.6% |
| Total Assets | ₹4056 Cr | ₹4679 Cr | ₹4638 Cr | ₹5015 Cr | ₹6155 Cr | +11.0% |
| Total Debt | ₹25.0 Cr | ₹35.6 Cr | ₹35.3 Cr | ₹47.4 Cr | ₹260 Cr | +79.6% |
| Shareholders' Equity | ₹3264 Cr | ₹3388 Cr | ₹3567 Cr | ₹3790 Cr | ₹4527 Cr | +8.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AJANTPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 JBCHEPHARM JBCHEPHARM | — | — | Pending | 17.1% | 46.7× |
 IPCALAB IPCALAB | — | — | Pending | 14.2% | 35.6× |
 WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
 ABBOTINDIA ABBOTINDIA | — | — | Pending | 32.5% | 35.5× |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹120.33/sh
Last payout
2025-11-10
₹28.00
Peak payout
₹28.00
Trailing yield
0.91%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Ajanta Pharma Limited (AJANTPHARM.NS) trades at 3074.90 vs a model fair value of 1276.33, a gap of -58.5%. Piotroski F-score: 5/9. Moat l...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AJANTPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AJANTPHARM →
Compare
Head-to-head with peers
Compare AJANTPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AJANTPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.